FDA Reshapes Drug Testing Approach - Top-Institutions - MDSpire

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

  • By

  • Kathryn Wighton

  • April 20, 2026

  • 2 min

Share

Top Institutions in Internal Medicine

Brief introduction explaining scope and methodology.

  • #1

    U.S. Food and Drug Administration (FDA)
    U.S. Food and Drug Administration (FDA)

    Silver Spring, MD

    Key Differentiators

    • Regulatory Science
    • Pharmacology
    • Toxicology
    • Computational Modeling

  • #2

    National Institutes of Health (NIH)
    National Institutes of Health (NIH)

    Bethesda, MD

    Key Differentiators

    • Biomedical Research
    • Pharmacology
    • Toxicology
    • Alternative Methods Development

  • #3

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Pharmacology
    • Toxicology
    • Computational Biology

  • #4

    Massachusetts Institute of Technology (MIT)
    Massachusetts Institute of Technology (MIT)

    Cambridge, MA

    Key Differentiators

    • Computational Biology
    • Pharmacology
    • Biomedical Engineering

  • #5

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Pharmacology
    • Toxicology
    • Regulatory Science

Original Source(s)

FDA Reshapes Drug Testing Approach

  • by Kathryn Wighton

  • April 20, 2026

Related Content

Identity Formation May Shape Residency Emotions

A review of 56 qualitative studies found residents' emotional experiences were influenced by interactions among training demands, workplace relationships, and their evolving professional identity.

Is Accelerated Aging Tied to Early-Onset Carcinogenesis?

Researchers found larger biological age gaps in more recent birth cohorts and observed associations with higher risk of several cancers diagnosed before age 55.

Can Belzutifan Improve Adjuvant Therapy?

The phase 3 LITESPARK-022 trial compared adjuvant pembrolizumab plus belzutifan with pembrolizumab plus placebo following resection of clear-cell renal-cell carcinoma.